CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer
June 25 2024 - 6:50AM
CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical
device company, today announced the appointment of Robert John as
Chief Revenue Officer effective June 27. In this role, John will
lead the Company's US sales team with the objective of maximizing
the positive impact of Barostim therapy on patients suffering from
heart failure and establishing Barostim as standard of care in the
United States.
"We are thrilled to welcome Robert to the CVRx executive team as
we continue to expand the adoption of Barostim therapy," said Kevin
Hykes, President and CEO of CVRx. "Robert is well-known and
respected within the heart failure community and has extensive
experience building global sales organizations, launching novel
heart failure therapies, and delivering results. He will be
invaluable as we accelerate our commercial momentum."
John brings over 25 years of sales leadership experience in the
medical device industry, with a strong track record of building
high-performing sales teams. Most recently, he served as Divisional
Vice President and General Manager of Cardiac Rhythm Management
EMEA at Abbott, where he led a global business unit spanning over
90 countries. Prior to this role, he was first Senior Vice
President, then the Divisional Vice President of the Heart Failure
business, responsible for integrating the Thoratec and CardioMEMs
businesses and leading the commercial teams for St. Jude, then at
Abbott post-acquisition. Prior to the acquisition, John held
multiple commercial leadership positions at St. Jude Medical across
the Cardiac Rhythm, Electrophysiology, Capital, Structural Heart,
Vascular and Heart Failure businesses. Prior to Abbott/St. Jude,
John held commercial roles at Medtronic, Guidant and Pfizer. He
holds a Bachelor of Science from the University of North Texas and
a Master of Arts in Human Resources Management from the University
of Alabama, Tuscaloosa.
"I am excited to join CVRx at this pivotal time for the company
and the patients we serve," said Robert John. "Throughout my
career, I have been passionate about bringing innovative therapies
to market that can significantly improve patient outcomes. CVRx's
Barostim therapy is a truly revolutionary technology with the
potential to transform the treatment of heart failure. I look
forward to working with the talented CVRx team to make this
groundbreaking therapy available to more patients and drive the
next phase of the company's growth."
About CVRx, Inc.
CVRx is focused on the development and commercialization of the
Barostimâ„¢ System, the first medical technology approved by FDA that
uses neuromodulation to improve the symptoms of heart failure.
Barostim is an implantable device that delivers electrical pulses
to baroreceptors located in the wall of the carotid artery.
Baroreceptors activate the body's baroreflex, which in turn
triggers an autonomic response to the heart. The therapy is
designed to restore balance to the autonomic nervous system and
thereby reduce the symptoms of heart failure. Barostim received the
FDA Breakthrough Device designation and is FDA-approved for use in
heart failure patients in the U.S. It has also received the CE Mark
for heart failure and resistant hypertension in the European
Economic Area. To learn more about Barostim, visit
www.cvrx.com.
Investor Contact:
Mark Klausner or Mike VallieICR
Westwicke443-213-0501ir@cvrx.com
Media Contact:
Laura O’NeillFinn
Partners402-499-8203laura.oneill@finnpartners.com
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From May 2024 to Jun 2024
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From Jun 2023 to Jun 2024